trending Market Intelligence /marketintelligence/en/news-insights/trending/RM9TVQPpeT38LKu3AxyFPw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biotechnology company Triplet Therapeutics launches with $59M in financing

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Biotechnology company Triplet Therapeutics launches with $59M in financing

Gene treatment biotechnology company Triplet Therapeutics Inc. has launched with $59 million in financing.

The company, which aims to treat disorders occurring as a result of DNA and RNA sequences expanding beyond a certain length, received $49 million from financing led by MPM Capital and Pfizer Inc.'s venture capital unit Pfizer Ventures U.S. LLC.

Atlas Venture, which co-founded Triplet and initially invested $10 million in it, also joined the round of financing alongside Invus, Partners Innovation Fund and Alexandria Venture Investments.

The company targets specific genetic activity by developing drug candidates that use antisense oligonucleotide — small pieces of DNA or RNA that bind to specific parts of genetic sequences — and small interfering RNA, which interferes with RNA at certain points of a sequence.

Triplet was founded in 2018 by Nessan Bermingham, a serial biotech entrepreneur and venture partner at Atlas Venture, along with Atlas Venture and Andrew Fraley.